HEXACATH
PIONEER IN BIO ACTIVE COATING

NEWS RELEASE

One Year Clinical Outcome of the 2000 Patients Enrolled in the Coronary Angioplasty Acute Myocardial Infarction Titan2 Bio Active Stent Registry: The CATS-AMI Registry.

EuroPCR, Paris, Late Breaking Trials, Hot Line Session, Friday, 20th May 2011, Room 342AB
Chairpersons: C.Di Mario, M.Sabaté, D.O Williams

During the late breaking registries and trial updates sessions held during the EuroPCR 2011 congress, the results of the large scale, multicenter, prospective registry "CATS-AMI" were presented by Dr Michaël Angioi (Institut Lorrain du Coeur et des Vaisseaux, Nancy University Hospital, France).

Between May 2008 and August 2010, 2137 patients have been enrolled in 38 french sites. The inclusion criteria were STEMI patients with culprit lesion treated by Titan2 bio-active stent: Primary PCI, rescue PCI following failed thrombolysis and PCI within 24 hours following successful thrombolysis as well as NSTEMI with culprit lesion treated within 72 hours.

Titan2 Bio Active Stent (BAS), Hexacath France, coated with a non-drug biological active compound called Titanium-Nitride-Oxide has shown low MACE rates of 3.6% at 1 month and 9.8% at 12 months in a particularly challenging and pro-thrombotic population. This large scale registry confirmed the previously reported Bio Active Stent results from both randomized and non-randomized studies and reinforces the existing body of evidence (17 existing scientific publications) supporting the efficacy and the safety profile of the Titan2 Bio Active Stent (BAS).

About Titanium-Nitride-Oxide
This bio-active compound has demonstrated to minimize inflammation and reduce platelet aggregation as well as fibrin deposition which makes a stent coated with Titanium-Nitride-Oxide less thrombogenic than any other stent technology BMS or DES.

About Titan2 Bio Active Stent
The Titan2 stent from Hexacath France, is a unique category of coronary stent which is neither a bare metal stent (BMS) nor a drug eluting stent (DES). This stent is coated with a biological active compound called Titanium-Nitride-Oxide. The mechanism of action of this compound while being less aggressive is similar to that found with several of the drugs used with (DES) whilst not carrying the side effects inherent to such drugs. The bio-active coating has shown to inhibit platelet

aggregation, fibrin deposition, promote re-endothelialization and minimize inflammation. Bio Active Stents coated with Titanium-Nitride-Oxide have demonstrated efficacy reducing neointimal proliferation and late loss versus uncoated bare metal stents (BMS) in previous published studies. Unlike drug eluting stents, the Titan2 Bio Active Stent is free of polymer, cytotoxic or cytostatic drugs which have been associated with impaired re-endothelialization explaining the compulsory need of prolonged dual antiplatelet treatment with current drug eluting stents to avoid late stent unwanted re-occlusion called thrombosis.

About Hexacath

Based in Rueil-Malmaison (Paris area), France, Hexacath is dedicated to develop, manufacture and distribute innovative cardiovascular products to improve patients treatments. Hexacath has expanded its product portfolio with vascular stents made of nitinol and cobalt chromium platforms coated with its patented biological active coating titanium nitride oxide. Besides, Hexacath has during the last 16 years open direct subsidiaries in France, Spain, Italy, UK, Belgium, Sweden, Finland, India, China, Brazil, Canada, Hong Kong, and is also distributed via distributors in 30 other countries.

Hexacath, 4, Passage St Antoine, 92508 Rueil-Malmaison, France
Tel : 00 33 1 41 39 01 90 – Fax : 00 33 1 41 39 01 93
Website :www.hexacath.com